With CE Mark approval, IMRIS will immediately commence marketing in Europe of two products: IMRISNV for stroke management and advanced neurovascular interventions and IMRIScardio for cardiovascular interventions.
According to IMRIS, IMRISNV features a 3T MRI scanner and a bi-plane angiography system specifically designed to co-exist in the same suite. Patients with acute ischemic stroke transition seamlessly from MR imaging to intervention without moving from the table. During and after the intervention, new MR images can be taken to assess the effectiveness of the treatment.
IMRISNV is designed to shorten transition time between imaging modalities, decrease the overall time for treatment and improve patient outcomes.
IMRIScardio features a 1.5T MRI scanner that provides images that can improve the physician’s ability to visualize the cardiovascular system before, during and after an intervention. With an integrated single-plane angiography system, IMRIScardio is designed to improve patient outcomes by decreasing the overall time for cardiovascular interventions and minimizing the patient’s exposure to radiation and contrast media, the company claimed.
David Graves, CEO of IMRIS, said: “CE Mark approval of our system represents our first step into the realm of neurovascular and cardiovascular interventional imaging. We are excited about launching our technology in Europe and we are confident that IMRISNV and IMRIScardio will help physicians and hospitals improve the outcomes of their patients suffering from a wide range of neurovascular and cardiovascular conditions.”